We are updating our list of tier-one Defensive Stocks since so many of these stocks have run up and since lists need continual updating. Our originally updated list of tier one defensive…
Early this week we are running a list of stocks that have been in a turnaround plan, yet the stocks and the businesses haven’t turned around. Could these be the stocks to…
James Tobin, the CEO of Boston Scientific (NYSE:BSX) is likely to find himself in front of the shareholder firing squad in 2008. In early 2004 this stock was above $40 and had…
According to Reuters, OPEC will probably keep oil output at current levels. Reuters writes that a goverment plan to help sub-prime borrowers will probably freeze their rates for five years. Reuters writes…
Abbott Labs (ABT) which just launched a new stent product, Xience V, has laid off 1,200 people because of slowness in the stent market. Stranger than fiction. According to MarketWatch, Abbott says…
Abbot Labs (ABT) is trying to get into the stent business. The market has been dominated by Boston Scientific (BSX) and Johnson & Johnson (JNJ). Stents are small mess implants which are…
Several studies which showed that stents could cause blood clotting in the heart have done significant damage to the revenue for those products at Boston Scientific (BSX) and Johnson & Johnson (JNJ).…
According to Reuters, BHP Billiton (BHP) will not sell its petroleum division, as had been rumored, to finance a bid for Rio Tinto (RTP). Reuters writes that most of the Hershey (HSY)…
The markets haven’t fallen apart after yesterday’s 360 point dive on the DJIA, but we are still trading a tad lower today. Now that Cisco Systems is showing you can’t just automatically…
Boston Scientific (BSX) did it shareholders a terrible disservice buy buying Guidant in a bidding war with Johnson & Johnson. It now has long-term debt of almost $8.3 billion. Troubles in its…
With the markets down so much today on the financial stock fallout after the Citi downgrade/concern and with oil stocks listing lower after the Exxon miss, we wanted to show a brief…
"William O’Neill, dean of clinical affairs at University of Miami’sMiller School of Medicine, says stent-patient traffic is beginning topick up in South Florida. Still, restoring luster to the popular deviceis likely to…
Shares of Amgen Inc. (NASDAQ:AMGN) are under bit of pressure this morning, although not from any direct news from the company itself. Luckily for Amgen, much of the bad news may already…
Johnson & Johnson (JNJ) announced third-quarter sales of $15.0 billion, an increase of 12.7% as compared to the third quarter of 2006.Net earnings and diluted earnings per share for the third quarter…
Douglas A. McIntyre Medtronic (MDT) got the FDA to approve its new drug-coated stent called the Endeavor. The agency did have some concerns about whether the product has long-term risks or whether it is more…
